Intrapulmonary potential of polyethylene glycol-modified glucagon-like peptide-1s as a type 2 anti-diabetic agent

Regulatory Peptides

Volumn 152, Issue 1-3, 2009, Pages 101-107

  Lee, Kang Choon ^a   Chae, Su Young ^a   Kim, Tae Hyung ^a   Lee, Seulki ^b   Lee, Eun Seong ^c   Youn, Yu Seok ^d  

^a Sungkyunkwan University   (South Korea)

^b Korea Institute of Science and Technology   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d Pusan National University   (South Korea)

Author keywords

Glucagon like peptide 1; PEGylation; Pharmacokinetics; Pulmonary delivery; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCOSE; IODINE 125; LUNG ENZYME; LYSINE; MACROGOL; MALEIC ANHYDRIDE; PEGYLATED GLUCAGON LIKE PEPTIDE 1; PEGYLATED GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CANNULATION; CONTROLLED STUDY; DRUG HALF LIFE; GLUCOSE BLOOD LEVEL; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MOLECULAR WEIGHT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; SYSTEMIC CIRCULATION; TISSUE DISTRIBUTION;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; GLUCAGON-LIKE PEPTIDE 1; HYPOGLYCEMIC AGENTS; INTUBATION, INTRATRACHEAL; MALE; MASS SPECTROMETRY; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 57249103364     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2008.09.008     Document Type: Article

References (31)

1. Nauck M.A. Effects of glucagon-like peptide-1 (GLP-1) on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 87 (2002) 1239-1246
2. Fehmann H.C., and Habener J.F. Insuliotropic hormone glucagon-like peptide I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology 130 (1992) 159-166
3. Turton M.D., O'Shea D., Gunn I., Beak S.A., Edwards C.M., Meeran K., Choi S.J., Taylor G.M., Heath M.M., Lambert P.D., Wilding J.P., Smith D.M., Ghatei M.A., Herbert J., and Bloom S.R. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379 (1996) 69-72
4. Deacon C.F. Therapeutic strategies based on glucagon-like peptide 1. Diabetes 53 (2004) 2181-2189
5. Cleland J.L., Daugherty A., and Mrsny R. Emerging protein delivery methods. Curr Opin Biotechnol 12 (2001) 212-219
6. Lee V.H.L., and Yamamoto A. Penetration and enzymatic barriers to peptide and protein absorption. Adv Drug Deliv Rev 4 (1990) 171-207
7. Wearley L.L. Recent progress in protein and peptide delivery by noninvasive routes. Crit Rev Ther Drug Carr Syst 8 (1991) 331-394
8. Patton J.S., and Byron P.R. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov 6 (2007) 67-74
9. Agu R.U., Ugwoke M.I., Armand M., Kinget R., and Verbeke N. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res 2 (2001) 198-209
10. Adjei A.L., and Gupta P.K. Inhalation delivery of therapeutic peptides and proteins (1997), Marcel Dekker, New York 107
11. Carino G.P., and Mathiowitz E. Oral insulin delivery. Adv Drug Deliv Rev 35 (1999) 249-257
12. Youn Y.S., Chae S.Y., Lee S., Jeon J.E., Shin H.G., and Lee K.C. Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment, insulinotropic activity, glucose-stabilizing capability, and proteolytic stability. Biochem Pharmacol 73 (2007) 84-93
13. Lee S., Youn Y.S., Lee S.H., Byun Y., and Lee K.C. PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db/db mice. Diabetologia 49 (2006) 1608-1611
14. Salhanick A.I., Clairmont K.B., Buckholz T.M., Pellegrino C.M., Ha S., and Lumb K.J. Contribution of site-specific PEGylation to the dipeptidyl peptidase IV stability of glucose-dependent insulinotropic polypeptide. Bioorg Med Chem Lett 15 (2005) 4114-4117
15. Uchio T., Baudys M., Liu F., Song S.C., and Kim S.W. Site-specific insulin conjugates with enhanced stability and extended action profile. Adv Drug Deliv Rev 35 (1999) 289-306
16. 18-amine specific PEGylation, Stability, permeability, pharmacokinetic behavior and in vivo hypocalcemic efficacy. J Control Release 114 (2006) 334-342
17. Caliceti P., and Veronese F.M. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 55 (2003) 1261-1277
18. Lee S.H., Lee S., Youn Y.S., Na D.H., Chae S.Y., Byun Y., and Lee K.C. Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1. Bioconjug Chem 16 (2005) 377-382
19. Youn Y.S., Na D.H., Yoo S.D., Song S.-C., and Lee K.C. Chromatographic separation and mass spectrometric identification of positional isomers of polyethylene glycol-modified growth hormone-releasing factor (1-29). J Chromatogr A 73 (2004) 84-93
20. Enna S.J., and Schanker L.S. Absorption of saccharides and urea from the rat lung. Am J Physiol 222 (1972) 409-414
21. Kobayashi S., Kondo S., and Juni K. Study on pulmonary delivery of salmon calcitonin in rats: effects of protease inhibitors and absorption enhancer. Pharm Res 11 (1994) 1239-1243
22. 1,7)-eel calcitonin by various protease inhibitors in rats. Pharm Res 11 (1994) 909-913
23. Yoo S.D., Jun H., Shin B.S., Lee H.S., Park M.O., DeLuca P.P., and Lee K.C. Pharmacokinetic disposition of polyethylene glycol-modified salmon calcitonin. Chem Pharm Bull 48 (2000) 1921-1924
24. Patton J.S., Fishburn C.S., and Weers J.G. The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc 1 (2004) 338-344
25. Barnett A.H., Lange P., Dreyer M., Serdarevic-Pehar M., and Exubera Phase 3 Study Group. Long-term tolerability of inhaled human insulin (Exubera) in patients with poorly controlled type 2 diabetes. Int J Clin Pract 61 (2007) 1614-1625
26. Hussain A., Arnold J.J., Khan M.A., and Ahsan F. Absorption enhancers in pulmonary protein delivery. J Control Release 94 (2004) 15-24
27. Ahren B. Enhancement or prolongation of GLP-1 activity as a strategy for treatment of type 2 diabetes. Drug Discov Today Ther Strateg 1 (2004) 207-212
28. Youn Y.S., Kwon M.J., Na D.H., Chae S.Y., Lee S., and Lee K.C. Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection. J Control Release 125 (2008) 68-75
29. Niven R.W., Whitcomb K.L., Shaner L., Ip A.Y., and Kinstler O.B. The pulmonary absorption of aerosolized and intratracheally instilled rhG-CSF and monoPEGylated rhG-CSF. Pharm Res 12 (1995) 1343-1349
30. Veronese F.M., and Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 10 (2005) 1451-1458
31. Fineberg S.E., Kawabata T., Finco-Kent D., Liu C., and Krasner A. Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes, an analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial. J Clin Endocrinol Metab 90 (2005) 3287-3294